← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Fzata, Inc.
Halethorpe, MD
$18,343,715
Total funding
8
Grants
Funding over time
peak $3.8M · FY2017–24$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,343,715 · 8
By mechanism
R01$8,100,504 · 1
R44$7,532,664 · 3
UG3$2,091,549 · 1
R43$618,998 · 3
Investigators at Fzata, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$2,154,339
R01 · FY2020 · AI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$2,138,618
R01 · FY2019 · AI
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome$2,091,549
UG3 · FY2024 · NS
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,460,626
R01 · FY2017 · AI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,170,960
R01 · FY2018 · AI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,008,708
R01 · FY2022 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$999,996
R44 · FY2021 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$988,488
R44 · FY2022 · AI
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$950,520
R44 · FY2023 · DK
A Yeast-based Immunotherapy against Clostridioides difficile infection$932,749
R44 · FY2022 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$923,175
R44 · FY2023 · AI
A Yeast-based Immunotherapy against Clostridioides difficile infection$906,503
R44 · FY2023 · AI
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$855,001
R44 · FY2022 · DK
A Yeast-based Immunotherapy against Clostridioides difficile infection$554,355
R44 · FY2021 · AI
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$252,416
R44 · FY2021 · DK
A Yeast based Immunotherapy against Clostridium difficile Infection$225,068
R43 · FY2017 · AI
Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease$224,999
R43 · FY2018 · AI
A Yeast-based Immunotherapy against Clostridioides difficile infection$169,461
R44 · FY2020 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection$168,931
R43 · FY2018 · AI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$167,253
R01 · FY2021 · AI